fewer injection attempts, and had a lower frequency of contrast leakage than out-of-plane needle guidance. The posterior glenohumeral approach was less technically demanding though had a higher frequency of contrast leakage and caused more patient discomfort than the rotator interval approach. For ultrasound-guided shoulderjointinjection, an in-plane approach is preferable. The posterior
to be superior to SSN PRF treatment. However, the follow up period was only 2 months and functional outcome was not assessed.In this RCT we investigate, if PRF of SSC and shoulder joint can improve functional outcome and reduce pain in sub-acute stroke patients with HSP compared to ICI. In addition, we want to study, if and how shoulderjointinjections in the meaning of pain treatment affect cervicocephalic secondary outcome we assess if shoulder pain treatment by shoulderjointinjection affects proprioception in shoulder joint and neck. We measure cervicocephalic kinaesthetic sensibility by the relocation test method introduced by Heikkilä 1996 (30). In kinaesthetic sensibility test, we use a target, laser pointer and measure the relocation accuracy (RA) in centimeters from the point on which the light
will be scheduled for 4-6 treatment appointments where they will undergo brachial plexus block and shoulderjointinjection by the anesthesiologist before passive mobilization performed by the chiropractor. Each passive mobilization treatment will be generally 20 minutes in duration. Care will be directed solely at the affected shoulder, and no other passive modalities will be applied other than manual
A randomised study of two training programmes for general practitioners in the techniques of shoulder injection To evaluate the impact of two different modes of shoulder injection training on the level of confidence and number of injections performed by general practitioners (GPs) Demographic details, and information on referrals for shoulder problems, shoulderjointinjection activity , and confidence in the six months before training were obtained for 40 GP principals at baseline. Standardised training in the techniques of shoulderjointinjection using rubber mannequins was given to all GPs. Twenty of these GPs were randomly allocated to receive additional training on patients in hospital joint injection clinics. Six months after both forms of training the shoulder injection and referral
Active Comparator: 20 mg Triamcinolone with 3cc of 1% Lidocaine20mg Triamcinolone with 3cc of 1% Lidocaine Drug: TriamcinoloneUltrasound guided glenohumeral shoulderjointinjection Active Comparator: 40 mg Triamcinolone with 3cc of 1% Lidocaine40mg Triamcinolone with 3cc of 1% Lidocaine Drug: TriamcinoloneUltrasound guided glenohumeral shoulderjointinjection Active Comparator: 80 mg Triamcinolone with 3cc of 1% Lidocaine80mg Triamcinolone with 3cc of 1% Lidocaine Drug: TriamcinoloneUltrasound guided glenohumeral shoulderjointinjection Outcome Measures Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Primary Outcome Measures : 1. Change in Overall SPADI Scores at Baseline Compared
shoulder 7. a previous fracture near the shoulder region 8. the presence of cervical radiculopathy or myelopathy 9. having received a corticosteroid or hyaluronic acid subacromial or shoulderjointinjection in the past 3 monthsContacts and LocationsGo to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
) 5. No fracture or subluxation or arthritis in shoulder Xray.B.Exclusion criteria： 1. History of shoulder or chest surgery 2. History of shoulder trauma in 2 recent years 3. Ever receiving shoulderjointinjection in recent 3 months 4. With cervical radiculopathy or any central CNS disorders 5. With osteoarthritis or rheumatic arthritis of shoulder 6. Diagnosed as rotator cuff tear, tendon